Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer

Institut de Cancérologie de Lorraine

Status: Completed

Conditions: Endometrial Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT02987777

ICL_2016_0001

Details and patient eligibility

About

The aim of this study was to assess the frequency of PD-L1 expression in stage III-IV ECs and to investigate its correlation impact with progression-free survival (PFS), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating CD8+ lymphocytes (TILs)

Enrollment: 80 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients consecutively enrolled from January 2004 to December 2014 treated for Endometrial cancer
• Stage III-IV endometrial cancer with available tissue blocks, including biopsies, hysterectomy specimens and resections of metastatic foci

Exclusion criteria

• A patient record captured outside the time frame from January 2004 to December 2014